How incidents impact congestion on roadways: A queuing network approach

In this paper we present a queuing network approach to the problem of routing and rebalancing a fleet of self-driving vehicles providing on-demand mobility within a capacitated road network. We refer to such systems as autonomous mobility-on-demand (AMoD) systems. We first cast an AMoD system into a closed, multi-class Baskett–Chandy–Muntz–Palacios (BCMP) queuing network model capable of capturing the passenger arrival process, traffic, the state-of-charge of electric vehicles, and the availability of vehicles at the stations. Second, we propose a scalable method for the synthesis of routing and charging policies, with performance guarantees in the limit of large fleet sizes. Third, we explore the applicability of our theoretical results on a case study of Manhattan. Collectively, this paper provides a unifying framework for the analysis and control of AMoD systems, which provides a large set of modeling options (e.g. the inclusion of road capacities and charging constraints), and subsumes earlier Jackson and network flow models.

Download Full-text

Queuing network approach for building evacuation planning

10.1063/1.4903638 ◽

2014 ◽

Cited By ~ 1

Author(s):

Nurhanis Ishak ◽

Ruzelan Khalid ◽

Md. Azizul Baten ◽

Mohd. Kamal Mohd. Nawawi

Keyword(s):

Evacuation Planning ◽

Network Approach ◽

Queuing Network ◽

Building Evacuation

Download Full-text

The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases

Emerging Topics in Life Sciences ◽

10.1042/etls20180178 ◽

2019 ◽

Vol 3 (1) ◽

pp. 97-105

Author(s):

Mary Zuccato ◽

Dustin Shilling ◽

David C. Fajgenbaum

Keyword(s):

Rare Diseases ◽

Treatment Options ◽

Castleman Disease ◽

High Impact ◽

Collaborative Network ◽

Network Approach ◽

Grant Applications ◽

Research Questions ◽

Novel Strategy ◽

Patient Centric

Abstract There are ∼7000 rare diseases affecting 30 000 000 individuals in the U.S.A. 95% of these rare diseases do not have a single Food and Drug Administration-approved therapy. Relatively, limited progress has been made to develop new or repurpose existing therapies for these disorders, in part because traditional funding models are not as effective when applied to rare diseases. Due to the suboptimal research infrastructure and treatment options for Castleman disease, the Castleman Disease Collaborative Network (CDCN), founded in 2012, spearheaded a novel strategy for advancing biomedical research, the ‘Collaborative Network Approach’. At its heart, the Collaborative Network Approach leverages and integrates the entire community of stakeholders — patients, physicians and researchers — to identify and prioritize high-impact research questions. It then recruits the most qualified researchers to conduct these studies. In parallel, patients are empowered to fight back by supporting research through fundraising and providing their biospecimens and clinical data. This approach democratizes research, allowing the entire community to identify the most clinically relevant and pressing questions; any idea can be translated into a study rather than limiting research to the ideas proposed by researchers in grant applications. Preliminary results from the CDCN and other organizations that have followed its Collaborative Network Approach suggest that this model is generalizable across rare diseases.

Download Full-text